Mirae Asset Global Investments Co. Ltd. Acquires 11,387 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD)

Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) by 4.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 270,396 shares of the company’s stock after purchasing an additional 11,387 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.90% of Relmada Therapeutics worth $1,119,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Stratos Wealth Partners LTD. bought a new position in shares of Relmada Therapeutics during the third quarter worth about $48,000. TD Asset Management Inc raised its holdings in Relmada Therapeutics by 100.0% during the 3rd quarter. TD Asset Management Inc now owns 25,000 shares of the company’s stock worth $75,000 after purchasing an additional 12,500 shares during the last quarter. Silverarc Capital Management LLC acquired a new position in shares of Relmada Therapeutics in the 3rd quarter worth approximately $300,000. Guild Investment Management Inc. boosted its stake in shares of Relmada Therapeutics by 84.0% in the 3rd quarter. Guild Investment Management Inc. now owns 205,300 shares of the company’s stock valued at $616,000 after purchasing an additional 93,750 shares during the last quarter. Finally, Parsons Capital Management Inc. RI increased its position in shares of Relmada Therapeutics by 11.5% during the third quarter. Parsons Capital Management Inc. RI now owns 974,082 shares of the company’s stock worth $2,922,000 after buying an additional 100,770 shares during the period. 45.24% of the stock is owned by institutional investors and hedge funds.

Relmada Therapeutics Stock Down 3.3 %

Shares of NASDAQ RLMD opened at $3.87 on Tuesday. The company has a market capitalization of $116.76 million, a PE ratio of -1.18 and a beta of 0.19. The firm has a fifty day simple moving average of $5.23 and a 200 day simple moving average of $3.98. Relmada Therapeutics, Inc. has a twelve month low of $2.36 and a twelve month high of $7.22.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings data on Tuesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.04. As a group, equities analysts expect that Relmada Therapeutics, Inc. will post -3.53 earnings per share for the current fiscal year.

Insider Buying and Selling at Relmada Therapeutics

In related news, CEO Sergio Traversa acquired 31,541 shares of the stock in a transaction dated Monday, January 29th. The stock was bought at an average price of $3.71 per share, for a total transaction of $117,017.11. Following the purchase, the chief executive officer now directly owns 175,565 shares of the company’s stock, valued at approximately $651,346.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Sergio Traversa purchased 31,541 shares of Relmada Therapeutics stock in a transaction on Monday, January 29th. The stock was acquired at an average cost of $3.71 per share, for a total transaction of $117,017.11. Following the completion of the acquisition, the chief executive officer now owns 175,565 shares of the company’s stock, valued at approximately $651,346.15. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Maged Shenouda purchased 10,800 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was bought at an average cost of $3.65 per share, with a total value of $39,420.00. Following the completion of the purchase, the chief financial officer now owns 13,028 shares of the company’s stock, valued at approximately $47,552.20. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 91,176 shares of company stock valued at $350,305. 13.50% of the stock is currently owned by company insiders.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.